The main purpose of the PLATFORM study is to evaluate the safety and efficacy of targeted drugs approved in China and to evaluate/test targeted therapy for specific tumor driver genes in patients with advanced rare solid tumor patients who have corresponding targets, as well as to evaluate the safety and efficacy of ICIs (PD-1 antibodies) in patients with advanced rare solid tumors who have no druggable target mutations. Here, PDCD1 is linked to neoplasm.